October 2, 2023 — Cyclopharm Limited (ASX: CYC) announces the company has received United States Food and Drug Administration (USFDA) approval to commence commercial sales of Technegas in the US market. The approval opens for Cyclopharm the single…Original Article
You may also like
Apellis Announces U.S. FDA Approval of the Empaveli...
FDA Approves Rivfloza (nedosiran) for the Treatment of...
FDA Approves Tofidence (tocilizumab-bavi), a...
FDA Approves Exxua (gepirone) for the Treatment of...
FDA Approves Pombiliti (cipaglucosidase alfa-atga) +...
U.S. FDA Approves Subcutaneous Administration of...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.